nference

#FlagshipFounded Valo Health announces a partnership with nference to accelerate human-centric drug discovery and development. ?

nference and Valo Health Announce Long-Term Partnership to Advance AI-Driven Drug Discovery nference is pleased to announce a multi-year collaboration with Valo Health, combining the capabilities of nference’s Agentic #AI platform with Valo’s Opal Computational Platform? to accelerate human-centric drug discovery and development. This partnership will leverage comprehensive, de-identified #multimodal patient insights from the nference federated AI network to: ? Enhance target discovery and biomarker identification ? Accelerate clinical translation with real-world evidence ? Shorten drug development timelines to bring critical treatments to patients more efficiently As nference continues to expand access to deep clinical and biomedical data, Valo will gain broader #insights to drive further innovations in precision medicine. Together, we aim to transform drug discovery by integrating AI-powered analytics with real-world patient data. Read more about this collaboration: https://lnkd.in/eUU5uY4N #Healthcare #RWE #PrecisionMedicine #DrugDiscovery #nference #ValoHealth #AgenticAI

The foundation of #AI-powered drug discovery starts with one key ingredient: high-quality #data. Next Wednesday, March 19th, Aaron Mathias, VP, Corporate Strategy at nference, will join an esteemed panel at Reuters Pharma USA 2025 to discuss the critical role of data integrity in AI-driven drug development. Panel Title: Garbage in, garbage out: Build a clean database Location: Pennsylvania Convention Center, Philadelphia Time: 9:40-10:20 AM EST Panel Participants: ? Hemanth Kanakamedala, VP, Decision Science and RWE at Recursion ? Arindam Mukherjee, Director, Data Strategy & Management at Ipsen ? Paul Murasko, Head of Digital Innovation and Marketing Operations at Azurity Pharmaceuticals ? John Androsavich, General Manager, Datapoints at Ginkgo Bioworks, Inc. Bioworks ? Manisha Sinha, Associate Director, Speciality Data Management at Regeneron The panel will explore how improving data quality and refining AI tools can ensure reliable, bias-free #insights to empower life science companies to make data-driven decisions with confidence. At nference, we are harnessing AI to de-identify, standardize, and curate #multimodal clinical data from leading medical institutions—including Mayo Clinic and Duke Health—to enable life sciences companies to accelerate drug development and #PrecisionMedicine. Join us at #ReutersPharmaUSA to explore how AI and real-world data can transform the future of medicine. Learn more about nference and how our AI-driven #RWE platform is transforming clinical research with real-world data: nference.com Request a live demo of the #AI platform: https://lnkd.in/eqWTyzTd #REpharmaUSA #PrecisionMedicine #ClinicalResearch #AIinHealthcare #RWD #ClinicalData #PatientData

nference is proud to support Blueprint Medicines in their mission to better understand the real-world burden and natural history of #ISM. Leveraging our #AI platform, researchers from Blueprint Medicines, Mayo Clinic and nference were able to analyze de-identified electronic health record data. The study revealed significant differences in healthcare utilization and #allergy prevalence for patients with ISM compared to matched controls. The findings that were presented today at #AAAAI25 reflect the importance of longitudinal real-world data in understanding the disease burden on ISM patients. Learn more about the AI platform powering breakthrough clinical research: https://lnkd.in/eqWTyzTd #Mastocytosis #RWE #PrecisionMedicine #AIinHealthcare #EHR

In our efforts to truly understand the experiences of people living with indolent systemic #mastocytosis (ISM), we work with partners to collect and analyze real-world data that inform our ability to improve and extend patients’ lives. At #AAAAI25 today, we're presenting findings from a study in partnership Dr. Thanai Pongdee to evaluate the real-world disease burden and natural history of ISM. This study involves the analysis of de-identified electronic health record data from the Mayo Clinic Platform via the nference Analytics Platform. Learn more below:

nference is sponsoring PMWC - Precision Medicine World Conference! Join nference at Booth #B803 this week to see a live demo of our #multimodal AI platform, nSights. Connect with our team today: Aaron Mathias Michiel JM Niesen Sadhna Kohli Jordan Sanford Kimberly Gasuad At nference, we’re committed to revolutionizing clinical research by combining advanced #AI models with comprehensive, de-identified multimodal data to unlock faster, more accurate outcomes. Our real-world evidence (#RWE) solutions—built in partnership with leading healthcare institutions—empower researchers to optimize #ClinicalTrial design, refine recruitment, and accelerate time-to-insight for novel therapies. Learn more about nference and how our AI-driven #nSights platform is transforming clinical research with real-world data: nference.com Request a live demo of the #nSights platform: https://lnkd.in/eqWTyzTd #PrecisionMedicine #ClinicalResearch #AIinHealthcare #RWD #LifeSciences #Genomics Tal Behar

Over 50% of new medicines face lengthy clinical trials, delaying patient access to breakthrough treatments. Leveraging #AI and advanced data platforms can significantly shorten the timeline for crucial efficacy readouts—bringing innovations to patients faster. nference’s Senior Director of Biomedical Research, Michiel JM Niesen, Ph.D., will join a distinguished panel at the PMWC - Precision Medicine World Conference on February 6th. The panel, titled “How to Implement AI for Faster Readouts of Clinical Trials,” will be chaired by William Oh, MD (Clinical Prof. of Medicine, Yale School of Medicine). Panel Participants: ? Jennifer Webster, VP, RWE Platforms & Partnerships at Pfizer ? Brandon Allgood, Ph.D., Chief Data Science Officer at Parabilis Medicines ? Julian Hong, MD, Assoc. Prof. & Medical Dir. of Radiation Oncology Informatics at University of California, San Francisco This forward-looking discussion will take place in the 'AI Models for RWE/D Applications' track, highlighting how AI tools, real-world data (#RWD), and collaborative platforms can accelerate #ClinicalTrial insights without compromising patient privacy. The nference team will be at Booth #B803 next week showcasing live demos of our #multimodal AI platform, nSights. Connect with our team to schedule a demo: Sadhna Kohli Jordan Sanford Kimberly Gasuad At nference, we’re committed to revolutionizing clinical research by combining advanced AI models with comprehensive, de-identified multimodal data to unlock faster, more accurate outcomes. Our real-world evidence solutions—built in partnership with leading healthcare institutions—empower researchers to optimize trial design, refine recruitment, and accelerate time-to-insight for novel therapies. Learn more about nference and how our AI-driven #nSights platform is transforming clinical research with real-world data: nference.com Request a live demo of our #nSights platform: https://lnkd.in/eqWTyzTd #PrecisionMedicine #ClinicalResearch #AIinHealthcare #RWE #LifeSciences #Genomics Tal Behar

Did you know? Over 1.5 million people worldwide are diagnosed with #BloodDisorders such as leukemia, lymphoma, and anemia each year. This underscores the urgent need for cutting-edge research and innovative treatments in hematology. Join nference at the American Society of Hematology (ASH) Annual Meeting this weekend to learn how we are advancing hematology research through real-world evidence and AI-driven insights. The ASH Annual Meeting is the premier event for leading experts, researchers, and clinicians to share breakthroughs in #Hematology research and patient care. Visit Booth #1557 to: ? Discover our federated data platform: Learn how we integrate fully de-identified longitudinal, #Multimodal data to tackle complex challenges in hematology, from rare blood disorders to hematologic malignancies. ? Leverage real-world evidence: Explore how our platform enhances #ClinicalTrial design, accelerates biomarker discovery, and improves patient care while maintaining the highest standards of data privacy and security. ? Experience a live demo: See our #nSights platform in action—combining AI insights from clinical notes, imaging, genomics, and laboratory data to deliver actionable, real-world evidence (#RWE). Connect with nference leaders: Aaron Mathias, VP, Business Development & Corporate Strategy AJ Venkatakrishnan, PhD, SVP,? A.I. Partnerships Sadhna Kohli, PhD, Director, Scientific Solutions Michiel JM Niesen, PhD, Senior Director of Biomedical Research Bruce Johnson, Biotech and Pharma Executive Allison Smither, PhD, Lead Research Scientist At nference, we are proud to partner with world-class institutions, including Mayo Clinic and Duke Health, to unlock the potential of de-identified healthcare data. Together, we are accelerating precision medicine and improving patient outcomes in difficult to treat and diagnose blood disorders. We look forward to connecting with you at #ASH to explore how our platform can support your research and clinical programs. Learn more about nference and our federated #nSights platform that is transforming healthcare through real-world data and AI: nference.com Request a live demo of the nSights #AI RWE platform: https://lnkd.in/eqWTyzTd #ASH2024 #HematologyInnovation #RealWorldEvidence #PrecisionMedicine #nference #AIinHealthcare

John Halamka, President of Mayo Clinic Platform Mayo Clinic describes four new #AI tools that are making #healthcare more powerful, more accurate and more #equitable. Learn more about how digital #technology, #data and AI can transform #health systems in the World Economic Forum report, Transforming Healthcare: Navigating Digital Health with a Value-Driven Approach:?https://ow.ly/kTXX50Ua7nA #HealthEquity

Congrats to the Anumana team for the latest recognition, this time from Fast Company’s ‘The 8 Next Big Technologies in Health for 2024” https://lnkd.in/efaM5j7J #Anumana - For #detecting #diseases #earlier Cardiovascular diseases remain the leading cause of death in the U.S. and across the globe. Anumana is tackling this by enhancing the utility of the electrocardiogram (ECG) with AI algorithms, so that clinicians can detect diseases earlier and more confidently. The ECG-AI algorithms were developed and trained using a real-world deep dataset from leading healthcare institutions and have been evaluated by the FDA.